Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.54 |
| ▸ | PRCP | P42785 | 3/20 | 0.47 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237294 | 1.00 | HCRTR1 (0.54) | HCRTR1HCRTR2PRCPPTGES | |
| SCHEMBL12423641 | 0.96 | HCRTR1 (0.59) | HCRTR1HCRTR2PRCPPTGES | |
| SCHEMBL29724469 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2PRCPPTGES | |
| SCHEMBL2706134 | 0.84 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL1293520 | 0.84 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL204028 | 0.84 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL1982286 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2PRCPPTGES | |
| SCHEMBL38658108 | 0.84 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL1982288 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2PRCPPTGES | |
| SCHEMBL12066828 | 0.83 | HCRTR1 (0.43) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-105985355-B | Fused tricyclic hepatitis virus inhibitor and application thereof | 南京圣和药业股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| EP-2692726-A1 | Anti-viral compounds | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2692346-A1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
| US-20120220562-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011050146-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092415-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
| US-20120220562-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | HCRTR1 893/4885HCRTR2 1648/4885PRCP 814/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
| US-20110092415-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
| US-20120172290-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.